Market Data
Market Cap₹44.36 Cr.
52W High₹27.99
Current Price₹5.35
52W Low₹4.76
Down from 52W High80.9 %
Face Value₹2
Performance
ROCE-92.18 %
ROE83.81 %
EPS (TTM)₹-17.24
EPS Prev Qtr₹-2
EPS Last Year₹-0.66
EBITDA Qtr₹-151.79 Cr.
Book Value₹-25
Financial Health
Debt/Equity-1.89
Debt/Profit-2.25
Total Assets₹753.48 Cr.
Promoter Holding7.57 %
Earning Power-23.69 %
Valuation
Industry P/E33.81
Price to Book-0.21
Price to Sales0.63
Key Metrics
Face Value
₹2
About Vivimed Labs Ltd
Healthcare · Pharmaceuticals
Vivimed Labs Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹2. Market cap ₹44.36 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a positive promoter holding of 7.57%, indicating some level of insider confidence.
Weaknesses
- The company reports a significant net loss of ₹-176.46 Cr against a revenue of ₹69.99 Cr, indicating severe operational inefficiencies.
- The P/E ratio of -0.29 and P/B ratio of -1.43 reflect negative earnings and book value, signaling financial distress.
- ROCE of -50.46% shows poor return on capital employed, highlighting ineffective use of assets.
- ROE of 501.75% is anomalously high due to negative equity, which is not sustainable and indicates a flawed capital structure.
- A negative Debt to Equity ratio of -10.7 suggests unusual accounting or severe financial strain, warranting caution.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 21.39 | 20.61 | 15.99 | 12 |
| ↳ QoQ Growth | - | -3.6% | -22.4% | -25.0% |
| Expenses | 26.68 | 26.47 | 31.54 | 163.79 |
| Operating Profit | -5.3 | -5.86 | -15.55 | -151.79 |
| OPM % | -24.78% | -28.43% | -97.25% | -1,264.92% |
| Other Income | 0.38 | 0.21 | 0 | 5.75 |
| Interest | 0.58 | 1.66 | 1 | 0.95 |
| Depreciation | 5.01 | 4.9 | 4.63 | 11.51 |
| EBITDA | -0.29 | -0.96 | -10.92 | -140.28 |
| EBITDA Margin % | -1.36% | -4.66% | -68.29% | -1,169% |
| Profit Before Tax | -5.49 | -7.3 | -16.55 | -146.99 |
| Tax % | 0% | 0% | 0% | -0.1% |
| Net Profit | -5.49 | -7.3 | -16.55 | -147.12 |
| ↳ QoQ Growth | - | -33.0% | -126.7% | -788.9% |
| EPS | -0.66 | -0.88 | -2 | -17.24 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 69.99 | 69.99 |
| Expenses | 248.48 | 248.48 |
| Operating Profit | -178.5 | -178.5 |
| OPM % | -255.04% | -255.04% |
| Other Income | 6.34 | 6.34 |
| Interest | 4.19 | 4.19 |
| Depreciation | 26.05 | 26.05 |
| Profit Before Tax | -176.33 | -176.33 |
| Tax % | -0.08% | -0.08% |
| Net Profit | -176.46 | -176.46 |
| EPS | -20.78 | -20.78 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
-
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
501.75%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 16.583 | 16.58 |
| Reserves | -51.752 | -227.14 |
| Borrowings | 376.33 | 397.31 |
| Other Liabilities | 579.67 | 566.73 |
| Total Liabilities | 920.835 | 753.48 |
| Fixed Assets | 407.672 | 237.01 |
| CWIP | 17.113 | 17.79 |
| Investments | 168.5 | 180.54 |
| Other Assets | 327.55 | 318.14 |
| Total Assets | 920.835 | 753.48 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | -1.751 |
| Cash from Investing Activity | -4.531 |
| Cash from Financing Activity | 4.964 |
| Net Cash Flow | -1.318 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 1857.44 |
| ROCE % | -50.12% |
Shareholding Pattern
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|
| Promoters % | 7.77% | 7.77% | 7.77% | 7.57% |
| FIIs % | 1.64% | 1.64% | 1.64% | 1.64% |
| DIIs % | 0% | 0% | 0% | 0% |
| Public % | 65.19% | 65.18% | 65.06% | 68.75% |
| No. of Shareholders | 48,928 | 48,925 | 49,221 | 47,492 |
Major Shareholders (>1%)
- Kitara Piin 1102Public Shareholding9.37%
- Varalwar SandeepPromoter and Promoter Group2.81%
- William F HarveyPublic Shareholding1.65%
- Sameer Mahendra SampatPublic Shareholding1.64%
As of 2026-03-31View all shareholders →